UK first to approve Moderna’s bivalent COVID-19 vaccine

On August 15, 2022, the UK Medicines and Healthcare Regulatory Agency (MHRA) announced the “conditional” approval of an “updated versions” of Moderna’s COVID-19 vaccine (mRNA-1273.214) for “boosters”, called Spikevax Bivalent, the first country in the world to do so.  This vaccine targets both extinct original Wuhan SARS-CoV-2 variant and the Omicron BA.1 variant, 25 micrograms of mRNA for each variant.   The government’s independent expert scientific advisory body endorsed the new vaccine type, “after carefully reviewing the evidence”. [1]

The approval was based on a single, incomplete human trial consisting of approximately 800 participants currently being conducted by Moderna.  It “triggers a strong immune response” against BA1 and a “good immune response” against sub variants BA.4 and BA.5 – the current prevalent strains!

Moderna’s CEO calls this the “next generation COVID-19 vaccine” and equates it to an iphone app.  The bivalant vaccine will be manufactured National Resilience, founded November 2020, with links to the CIA.